Apellis Pharmaceuticals announces plan to slash workforce by 25%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Raymond James Reiterates Strong Buy Rating on Apellis Pharmaceuticals (APLS), 'a signal of commitment to and confidence in Syfovre'
August 29, 2023 3:16 PM EDTRaymond James analyst Steven Seedhouse reiterated a Strong Buy rating and $89.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS)
The analyst comments "We remain at a Strong Buy rating on APLS following an announced cost savings program. Apellis restructuring announcement sends an interesting signal at an... More
Apellis Pharmaceuticals (APLS) PT Raised to $54 at Citi, 'Corporate Restructuring Not Overly Surprising'
August 29, 2023 3:15 PM EDTCiti analyst Yigal Nochomovitz raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $54.00 (from $45.00) while maintaining a Buy rating.
The analyst comments "We are inferring based on timing of restructuring that Apellis revised internal projections for the Syfovre launch following the ROV disclosures are... More
